07:36 AM EDT, 10/16/2025 (MT Newswires) -- Merck ( MRK ) said Thursday its phase 3 trial evaluating its cancer drug Keytruda in combination with chemotherapy with or without bevacizumab met its secondary endpoint of overall survival in patients with platinum-resistant recurrent ovarian cancer.

The drug previously met its primary endpoint of progression free survival in patients with platinum-resistant recurrent ovarian cancer whose tumors express PD-L1, as well as its secondary endpoint of overall survival for patients whose tumors express PD-L1, at previous interim analysis.

The Keytruda-based regimen demonstrated a 'statistically significant and clinically meaningful improvement' in overall survival in all comers compared with placebo plus chemotherapy with or without bevacizumab, the company said.

The trial showed no new safety signals for Keytruda as the safety profile remained consistent with that observed in previously reported studies, Merck ( MRK ) said.